The 58 references in paper L. Dvoretsky I., Л. Дворецкий И. (2014) “Ключевые вопросы антибактериальной терапии обострений хронической обструктивной болезни легких // Key points of antibacterial therapy of acute exacerbation of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2011:i:4:p:87-96

1
Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418–1422.
(check this in PDF content)
2
Anthonisen N.R., Manfreda J., Warren C.P. et al.Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
(check this in PDF content)
3
Elmes P.C., King T.K., Langlands J.H. et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br. Med. J. 1965; 2: 904–908.
(check this in PDF content)
4
Jorgensen A.F., Coolidge J., Pedersen P.A. et al.Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis: a double-blind, placebo-controlled multicentre study in general practice. Scand. J. Prim. Hlth Care 1992; 10: 7–11.
(check this in PDF content)
5
Nouira S., Marghli S., Belghith M. et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020–2025.
(check this in PDF content)
6
Pines A., Raafat H., Plucinski K. et al.Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. Br. Med. J. 1968; 2: 735–738.
(check this in PDF content)
7
Allegra L.,Grassi C., Grossi E., Pozzi E. Ruolo degli antidiotici nel trattamento delle riacutizza della bronchite cronica. Ital. J. Chest Dis. 1991; 45: 138–148.
(check this in PDF content)
8
Saint S., Bent S., Vittinghof E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J.A.M.A. 1995; 273; 957–960.
(check this in PDF content)
9
Ram F., Rodriguez)Roisin R., Granados)Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 3.
(check this in PDF content)
10
Puhan M., Vollenweider D., Latshang T. et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007; 8: 30.
(check this in PDF content)
11
Blasi F., Ewig S., Torres A., Huchon G. A review of guidelines for antibacterial use in acute exacerbations of chronic bronchitis. Pulm. Pharmacol. Ther. 2006; 19: 361–369.
(check this in PDF content)
12
Beghi G., Berni F., Carratu L. et al.Efficacy and tolerability of azithromycin versus amoxicillin / clavulanic acid in acute purulent exacerbation of chronic bronchitis. J. Chemother 1995; 7: 146–152.
(check this in PDF content)
13
Anzueto A., Fisher C.L.Jr., Busman T., Olson C.A. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin / clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 72–86.
(check this in PDF content)
14
Martinot J.B., Carr W.D., Cullen S. et al.A comparative study of clarithromycin modified release and amoxicillin / clavulanic acid in the treatment of acute exacerbation of chronic bronchitis. Adv. Ther. 2001; 18: 1–11.
(check this in PDF content)
15
Hoepelman I.M., Mollers M.J., van Schie M.H. et al.A short (3-day) course of azithromycin tablets versus a 10-day course of amoxicillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int. J. Antimicrob. Agents 1997; 9: 141–146.
(check this in PDF content)
16
Martinez F.J., Grossman R.F., Zadeikis N. et al.Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg. Eur. Respir. J. 2005; 25: 1001–1010.
(check this in PDF content)
17
Starakis I., Gogos C.A., Bassaris H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis. Int. J. Antimicrob. Agents 2004; 23: 129–137.
(check this in PDF content)
18
Schaberg T., Ballin I., Huchon G. et al. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J. Int. Med. Res. 2001; 29: 314–328.
(check this in PDF content)
19
File T., Schlemmer B., Garau J. et al.Gemifloxacin versus amoxicillin / clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study Group. J. Chemother. 2000; 12: 314–325.
(check this in PDF content)
20
Siempos I., Dimopoulos G., Korbila I. et al.Macrolides, quinolones and amoxicillin / clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007; 29: 1127–1137.
(check this in PDF content)
21
Dooley K.E., Golub J., Goes F.S. et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin. Infect. Dis. 2002; 34: 1607–1612.
(check this in PDF content)
22
Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932–946.
(check this in PDF content)
23
Chang K.C., Leung C.C. Meta-analysis may not be practicable for guiding antibiotic therapy. Eur. Respir. J. 2008; 31: 906–907.
(check this in PDF content)
24
WHO model prescribing information. Drugs used in bacterial infections. Geneva: WHO; 2001.
(check this in PDF content)
25
Neu H.C., Wilson A.P., GrunebergR.N. Amoxycillin / clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J. Chemother. 1993; 5: 67–93.
(check this in PDF content)
26
Garau J., Twynholm M., Garcia)Mendez E. et al.Oral pharmacokinetically enhanced co-amoxiclav 2000 / 125 mg, twice daily, compared with co-amoxiclav 875 / 125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J. Antimicrob. Chemother. 2003; 52: 826–836.
(check this in PDF content)
27
Henry D.C., Riffer E., Sokol W.N. et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob. Agents Chemother. 2003; 47: 2770–2774.
(check this in PDF content)
28
File T.M.Jr., Lode H., Kurz H. et al. Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin-clavulanate (2,000 / 125 milligrams) versus those of amoxicillin-clavulanate (875 / 125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2004; 48: 3323–3331.
(check this in PDF content)
29
Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin / clavulanic acid versus the originator filmcoated tablet. Int. J. Clin. Pharmacol. Ther. 2001; 39: 75–82.
(check this in PDF content)
30
Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология 2008; 2: 73–80.
(check this in PDF content)
31
Wilkinson T.M., Donaldson A., Gavin C. et al.Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004, 169:1298–1303.
(check this in PDF content)
32
Rothberg M.B., Pekow P.S., Lahti M. et al.Аntibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. J.A.M.A. 2010; 303 (20): 2035–2042.
(check this in PDF content)
33
Falagas M.E., Avgeri S.G., Matthaiou D.K. et al. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J. Antimicrob. Chemother. 2008; 62 (3): 442–450.
(check this in PDF content)
34
El Moussaoui R., Roede B.M., Speelman P. et al. Shortcourse antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63 (5): 415–422.
(check this in PDF content)
35
Roede B.M., Bresser P., El Moussaouri R. et al. Three vs 10 days of amoxicillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomized, double-blind study. Clin. Microbiol. Infect. 2007; 13: 284–290.
(check this in PDF content)
36
Pechere J.C.Modeling and predicting clinical оutcomes of antibiotic therapy. Infect. Med. 1998; 15 (Suppl. E): 46–50.
(check this in PDF content)
37
Wilson R., Allegra L., Huchon G. et al. Short and long outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB). The MOSAIC study. Eur. Respir. J. 2003; 22 (Suppl. 45): 3559A.
(check this in PDF content)
38
Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Клинико-микробиологический мониторинг больных с обострением хронического бронхита, леченных антибактериальными препаратами. Тер. арх. 2006; 3:25–35.
(check this in PDF content)
39
Anzueto A., Rizzo J., Grossman R.The infection-free interval: its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis. Clin. Infect. Dis. 1999; 28: 1344–1345.
(check this in PDF content)
40
Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–2236.
(check this in PDF content)
41
White A.J., Gompertz S., Bayley D.L. et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–685.
(check this in PDF content)
42
Miravitlles M.Grupo de trabajo de la Asociacion Latinoamericana del Torax (ALAT). Update to the Latin American Thoracic Association (ALAT) recommendations on infectious exacerbation of chronic obstructive pulmonary disease. Arch. Bronconeumol. 2004; 40: 315–325.
(check this in PDF content)
43
Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Инфекционное обострение хронической обструктивной болезни легких. (Практические рекомендации по диагностике, лечению и профилактике). Рос. мед. вестн. 2006; 12: 4–18.
(check this in PDF content)
44
Albertson Т.E., Chan A.L. Antibiotic Therapy in elderly patients with acute exacerbation of chronic bronchitis. Exp. Rev. Respir. Med. 2009; 3 (5): 539–548.
(check this in PDF content)
45
Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–1548.
(check this in PDF content)
46
Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. и антимикроб. химиотер. 2006; 8 (1): 33–47.
(check this in PDF content)
47
Филимонова О.Ю., Грудинина С.А., Сидоренко С.В. и др. Антибиотикорезистентность штаммов Haemophilus influenzae, выделенных в Москве с 2002 по 2004 гг. Антибиотики и химиотер. 2004; 49 (12): 14–20.
(check this in PDF content)
48
Jacobs M.R., Felmingham D., Appelbaum P.C. et al. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 2003; 52: 229–246.
(check this in PDF content)
49
Авдеев С.Н., Шанина А.Г., Чучалин А.Г. Бактериальная инфекция у больных ХОБЛ с острой дыхательной недостаточностью. Клин. микробиол. и антимикроб. химиотер. 2005; 7 (3): 245–254.
(check this in PDF content)
50
Esel D., Ay)Altintop Y., Yagmur G. et al. Evaluation of susceptibility patterns and BRO beta-lactamase types among clinical isolates of Moraxella catarrhalis. Clin. Microbiol. Infect. 2007; 13: 1023–1025.
(check this in PDF content)
51
Beekmann S.E., Heilmann K.P., Richter S.S. et al. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002–2003. Results of the multinational GRASP Surveillance Program. Int. J. Antimicrob. Agents 2005; 25: 148–156.
(check this in PDF content)
52
Pankuch G.A., Jueneman S.A., Davies T.A. et al. In vitro selection of resistance to four beta-lactams and azitromycin in S. pneumoniae. Antimicrob. Agents Chemother. 1998; 42: 2914–2918.
(check this in PDF content)
53
Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002, 347, 465–471.
(check this in PDF content)
54
Bont J., Hak E., Birkhoff C.E. et al.Is co-morbidity taken into account in the antibiotic management of elderly patients with acute bronchitis and COPD exacerbations? Fam. Pract. 2007; 24 (4): 317–322.
(check this in PDF content)
55
Pechere J., Hughes D., Kardas P., Cornaglia G. Non compliance with antibiotic therapy for acute community infections: a global survey. Int. J. Antimicrob. Agents 2007; 29: 245–253.
(check this in PDF content)
56
Kardas P.Comparison of patient compliance with oncedaily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J. Аntimicrob. Сhemother. 2007; 59 (3): 531–536.
(check this in PDF content)
57
Niederman M.S. What are the benefits of antibiotics in acute exacerbations of COPD? In: 13thERS annual congress, Vienna; 2003.
(check this in PDF content)
58
Wistrom J., Norrby S.R., Myhre E.B. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 2001: 47 (1): 43–50. Информация об авторе
(check this in PDF content)